A-6880 17-AAG, >99% [17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin] M.W. 585.69 C31H43N3O8 [75747-14-7] Warning: Toxic. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.” Cancer Chemother. Pharmacol. 42: 273-279 (1998). •Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. “Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.” Oncogene 21: 1159-1166 (2002). •Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. “A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.” Nature 425: 407-10 (2003). •Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. “Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.” J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. “Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.” Cancer Res. 63: 2139-2144 (2003). •Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. “Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.” Mol Pharmacol. 65: 235-243 (2004). •Inhibits angiogenesis. Kaur, G, et al. “Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.” Clin. Cancer Res. 10: 4813-4821 (2004). •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
A-6880 17-AAG, >99% [17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin] M.W. 585.69 C31H43N3O8 [75747-14-7] Warning: Toxic. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.” Cancer Chemother. Pharmacol. 42: 273-279 (1998). •Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. “Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.” Oncogene 21: 1159-1166 (2002). •Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. “A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.” Nature 425: 407-10 (2003). •Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. “Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.” J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. “Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.” Cancer Res. 63: 2139-2144 (2003). •Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. “Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.” Mol Pharmacol. 65: 235-243 (2004). •Inhibits angiogenesis. Kaur, G, et al. “Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.” Clin. Cancer Res. 10: 4813-4821 (2004). •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
A-6880 17-AAG, >99% [17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin] M.W. 585.69 C31H43N3O8 [75747-14-7] Warning: Toxic. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.” Cancer Chemother. Pharmacol. 42: 273-279 (1998). •Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. “Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.” Oncogene 21: 1159-1166 (2002). •Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. “A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.” Nature 425: 407-10 (2003). •Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. “Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.” J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. “Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.” Cancer Res. 63: 2139-2144 (2003). •Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. “Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.” Mol Pharmacol. 65: 235-243 (2004). •Inhibits angiogenesis. Kaur, G, et al. “Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.” Clin. Cancer Res. 10: 4813-4821 (2004). •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
A-6880 17-AAG, >99% [17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin] M.W. 585.69 C31H43N3O8 [75747-14-7] Warning: Toxic. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.” Cancer Chemother. Pharmacol. 42: 273-279 (1998). •Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. “Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.” Oncogene 21: 1159-1166 (2002). •Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. “A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.” Nature 425: 407-10 (2003). •Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. “Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.” J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. “Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.” Cancer Res. 63: 2139-2144 (2003). •Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. “Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.” Mol Pharmacol. 65: 235-243 (2004). •Inhibits angiogenesis. Kaur, G, et al. “Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.” Clin. Cancer Res. 10: 4813-4821 (2004). •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
A-6880 17-AAG, >99%[17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin] M.W. 585.69 C31H43N3O8 [75747-14-7] Warning: Toxic. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.” Cancer Chemother. Pharmacol. 42: 273-279 (1998).•Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. “Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.” Oncogene 21: 1159-1166 (2002).•Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. “A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.” Nature 425: 407-10 (2003).•Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. “Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.” J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. “Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.” Cancer Res. 63: 2139-2144 (2003).•Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. “Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.” Mol Pharmacol. 65: 235-243 (2004).•Inhibits angiogenesis. Kaur, G, et al. “Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.” Clin. Cancer Res. 10: 4813-4821 (2004).•Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. -20 ºC
A-6880 17-AAG, >99% [17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin] M.W. 585.69 C31H43N3O8 [75747-14-7] Warning: Toxic. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A View the MSDS for this product Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. "The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin." Cancer Chemother. Pharmacol. 42: 273-279 (1998). Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. "Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2." Oncogene 21: 1159-1166 (2002). Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors." Nature 425: 407-10 (2003). Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. "Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin." J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. "Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol." Cancer Res. 63: 2139-2144 (2003). Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. "Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines." Mol Pharmacol. 65: 235-243 (2004). Inhibits angiogenesis. Kaur, G, et al. "Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator." Clin. Cancer Res. 10: 4813-4821 (2004). Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
A-6880 17-AAG, >99% [17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin] M.W. 585.69 C31H43N3O8 [75747-14-7] Warning: Toxic. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.” Cancer Chemother. Pharmacol. 42: 273-279 (1998). •Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. “Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.” Oncogene 21: 1159-1166 (2002). •Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. “A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.” Nature 425: 407-10 (2003). •Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. “Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.” J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. “Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.” Cancer Res. 63: 2139-2144 (2003). •Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. “Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.” Mol Pharmacol. 65: 235-243 (2004). •Inhibits angiogenesis. Kaur, G, et al. “Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.” Clin. Cancer Res. 10: 4813-4821 (2004). •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
A-6880 17-AAG, >99% [17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin] M.W. 585.69 C31H43N3O8 [75747-14-7] Warning: Toxic. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.” Cancer Chemother. Pharmacol. 42: 273-279 (1998). •Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. “Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.” Oncogene 21: 1159-1166 (2002). •Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. “A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.” Nature 425: 407-10 (2003). •Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. “Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.” J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. “Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.” Cancer Res. 63: 2139-2144 (2003). •Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. “Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.” Mol Pharmacol. 65: 235-243 (2004). •Inhibits angiogenesis. Kaur, G, et al. “Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.” Clin. Cancer Res. 10: 4813-4821 (2004). •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
A-6880 17-AAG, >99% [17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin] M.W. 585.69 C31H43N3O8 [75747-14-7] Warning: Toxic. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.” Cancer Chemother. Pharmacol. 42: 273-279 (1998). •Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. “Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.” Oncogene 21: 1159-1166 (2002). •Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. “A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.” Nature 425: 407-10 (2003). •Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. “Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.” J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. “Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.” Cancer Res. 63: 2139-2144 (2003). •Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. “Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.” Mol Pharmacol. 65: 235-243 (2004). •Inhibits angiogenesis. Kaur, G, et al. “Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.” Clin. Cancer Res. 10: 4813-4821 (2004). •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
17-AAG Description An anologue of geldanamycin. It is a Hsp90 antagonist that induces apoptosis in human leukemia cells. It has been shown to enhance paclitaxel-mediated cytotoxicity and down-regulate vascular endothelial factor expression. Specifications Cas No. 75747-14-7 Product ID A0025 Product Name 17-AAG Synonym 17-(Allylamino)-17-desmethoxy-geldanamycin; allylaminogeldanamycin Formula Wt. 585.69 Melting Point 200oC-205oC Purity ≥97% Solubility Soluble in DMSO or methanol. Stability Protect from light. Store Temp +4oC Ship Temp Ambient References Rahmani M, Yu C, Dai Y et al. Cancer Research. 63:8420-7 (2003). Nguyen DM, Lorang D, Chen GA et al. Annals of Thoracic Surgery. 72:371-8 (2001).
17-AAG Description An anologue of geldanamycin. It is a Hsp90 antagonist that induces apoptosis in human leukemia cells. It has been shown to enhance paclitaxel-mediated cytotoxicity and down-regulate vascular endothelial factor expression. Specifications Cas No. 75747-14-7 Product ID A0025 Product Name 17-AAG Synonym 17-(Allylamino)-17-desmethoxy-geldanamycin; allylaminogeldanamycin Formula Wt. 585.69 Melting Point 200oC-205oC Purity ≥97% Solubility Soluble in DMSO or methanol. Stability Protect from light. Store Temp +4oC Ship Temp Ambient References Rahmani M, Yu C, Dai Y et al. Cancer Research. 63:8420-7 (2003). Nguyen DM, Lorang D, Chen GA et al. Annals of Thoracic Surgery. 72:371-8 (2001).
17-AAG Description An anologue of geldanamycin. It is a Hsp90 antagonist that induces apoptosis in human leukemia cells. It has been shown to enhance paclitaxel-mediated cytotoxicity and down-regulate vascular endothelial factor expression. Specifications Cas No. 75747-14-7 Product ID A0025 Product Name 17-AAG Synonym 17-(Allylamino)-17-desmethoxy-geldanamycin; allylaminogeldanamycin Formula Wt. 585.69 Melting Point 200oC-205oC Purity ≥97% Solubility Soluble in DMSO or methanol. Stability Protect from light. Store Temp +4oC Ship Temp Ambient References Rahmani M, Yu C, Dai Y et al. Cancer Research. 63:8420-7 (2003). Nguyen DM, Lorang D, Chen GA et al. Annals of Thoracic Surgery. 72:371-8 (2001).
17-AAG 17-Allylamino-17-demethoxygeldanamycin- An Hsp90 inhibitor 17-Allylamino-17-demethoxygeldanamycin (17AAG) is a less toxic and more stable analog of geldanamycin (GA) [1]. Even though 17-AAG binding to Hsp90 is weaker than GA,17-AAG displays similar antitumor effects as GA and a better toxicity profile. 17-AAG is currently in phase I clinical trial in several centers worldwide. Preliminary data obtained from these trials demonstrate that antitumor activity is achieved at concentrations below the maximum tolerated dose [2]. Working concentration: 10 nM – 10 μM CAS number: 75747-14-7 Formula: C31H43N3O8 Molecular weight: 586 Solubility: Soluble in DMSO (10 mg/ml)
